Checkpoint Surgical said it has completed a$9 million financing round. The Cleveland-based company is a specialist in nerve protection and repair. The financing was led by Mutual Capital Partners, existing backers included First Analysis, a growth equity firm based in Chicago, the JumpStart Next Fund and several individual investors.

Checkpoint said the growth capital will be used to expand Checkpoint’s sales and marketing resources, advance new product/market opportunities in nerve regeneration and neuroma pain, as well as bolster Checkpoint’s executive team.

“We spoke with many of Checkpoint’s surgeon-users and distributors and were impressed with the enthusiasm expressed by key opinion leaders at world renowned medical institutions using Checkpoint’s technology,” Wayne Wallace of Capital Partners said in a release. “Checkpoint has the core technology and team needed to build a significant business in a large high-growth market. We look forward to helping the team build on prior success in the nerve protection and repair space.”